<DOC>
	<DOCNO>NCT02830477</DOCNO>
	<brief_summary>The primary objective study investigate weekly prophylaxis dose regimen use standard clinical practice . In addition study capture report bleed rate , pattern change KOVALTRY prophylaxis dose &amp; dosing frequency , reason choice treatment regimen , FVIII product switch pattern , patient treatment satisfaction adherence , KOVALTRY pharmacokinetic data ( perform ) , KOVALTRY consumption , well safety data .</brief_summary>
	<brief_title>Study Evaluating `` Real World '' Treatment Pattern Previously Treated Hemophilia A Patients Receiving KOVALTRY ( Octocog Alfa ) Routine Prophylaxis</brief_title>
	<detailed_description>Open label , prospective , non-interventional , single arm study patient receive KOVALTRY prophylaxis therapy .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient diagnose moderate severe hemophilia A ( ≤ 5 % Factor VIII level ) Any age ≥ 50 exposure day ( EDs ) FVIII product Patients history inhibitor Currently ( start within 3 month study enrollment ) plan start prophylaxis therapy KOVALTRY Written inform consent Patients participate investigational program intervention outside routine clinical practice Patients additional diagnosis bleeding/coagulation disorder hemophilia A</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Previously treat patient</keyword>
</DOC>